Claims for Patent: 7,959,999

Summary for Patent: 7,959,999

Title:	Hybrid stent and method of making
Abstract:	A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and outer polymeric materials can be of the same polymer or different polymer to achieve different results, such as enhancing flexibility and providing a stent that is visible under MRI, computer tomography and x-ray fluoroscopy.
Inventor(s):	Prabhu; Santosh (San Jose, CA)
Assignee:	Abbott Cardiovascular Systems, Inc. (Santa Clara, CA)
Application Number:	11/832,091
Patent Claims:	1. A stent, comprising: a plurality of metallic rings aligned along a stent longitudinal axis; an outer layer of a first polymeric material covering an outer surface of the metallic rings; an inner layer of a second polymeric material covering an inner surface of the metallic rings, the inner layer being bonded directly to the outer layer in areas where there is no metallic rings; and at least two discrete links connecting adjacent metallic rings together, each of the discrete links being formed in the area where the outer layer is directly bonded to the inner layer. 2. The stent of claim 1, wherein the first polymeric material is EVOH. 3. The stent of claim 1, wherein the second polymeric material is PEEK. 4. The stent of claim 3, wherein the PEEK is radiopaque. 5. The stent of claim 2, wherein the EVOH is radiopaque. 6. The stent of claim 1, wherein the first and second polymeric materials are taken from the group of polymers consisting of polyetheretherketone (PEEK), ethyl vinyl alcohol (EVOH), polyetherketone, polymethylmethacrylate, polycarbonate, polyphenylenesulfide, polyphenylene, polyvinylfluoride, polyvinylidene fluoride, polypropylene, polyethylene, poly(vinylidene fluoride-co-hexafluoropropylene), poly(ethylene-co-hexafluoropropylene), poly(tetrafluoroethyelene-co-hexafluoropropylene), poly(tetrafluoroethyelene-co-ethylene), polyethyleneterephthalate, polyimides, polyetherimide, ePTFE, polyurethanes, polyetherurethanes, polyesterurethanes, silicone, thermoplastic elastomer, polyether-amide thermoplastic elastomer, fluoroelastomers, fluorosilicone elastomer, styrene-butadiene-styrene rubber, styrene-isoprene-styrene rubber, polybutadiene, polyisoprene, neoprene, ethylene-propylene elastomer, chlorosulfonated polyethylene elastomer, butyl rubber, polysulfide elastomer, polyacrylate elastomer, nitrile rubber, a family of elastomers composed of styrene, ethylene, propylene, aliphatic polycarbonate polyurethane, polymers augmented with antioxidants, polymers augmented with image enhancing materials, polymers having a proton (H+) core, butadiene and isoprene and polyester thermoplastic elastomer and a di-block co-polymer of PET and caprolactone. 7. The stent of claim 1, wherein the metallic rings are formed of a metal alloy taken from the group of metal alloys consisting of stainless steel, titanium, tantalum, nickel-titanium, cobalt-chromium, and tungsten. 8. The stent of claim 1, wherein one or both of the first and second polymeric materials are loaded with a therapeutic drug. 9. The stent of claim 8, wherein the therapeutic drug is taken from the group of drugs including one or more of everolimus, rapamycin, actinomycin D (ActD), or derivatives and analogs thereof; synonyms of actinopmycin D including dactinomycin, actinomycin IV, actinomycin 11, actinomycin X1, and actinomycin C1; antiproliferative substances including antineoplastic, antinflammatory, antiplatelet, anticoagulant, antifibrin, antithomobin, antimitotic, antibiotic, antioxidant substances, taxol (paclitaxel and docetaxel), anticoagulants, antifibrins, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein, IIb/IIIa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, mutamycin; angiopeptin, angiotensin converting enzyme inhibitors; calcium channel blockers; colchicine fibroblast growth factor (FGF) antagonists; fish oil (omega 3-fatty acid); histamine antagonist; monoclonal antibodies (such as PDGF receptors); nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitor (a PDGF antagonist); serotonin blockers; steroids; thioprotease inhibitors; triazolopyrimidine (a PDGF antagonist); and nitric oxide. 10. The stent of claim 1, wherein a radiopaque marker is positioned between the first polymeric material and the second polymeric material. 11. The stent of claim 1, wherein the outer layer of the first polymeric material has a thickness in the range of 0.001 mm to 2.5 mm. 12. The stent of claim 11, wherein the outer layer has a uniform thickness. 13. The stent of claim 11, wherein the outer layer has a variable thickness. 14. The stent of claim 1, wherein the inner layer of the second polymeric material has a thickness in the range of 0.001 mm to 2.5 mm. 15. The stent of claim 14, wherein the inner layer has a uniform thickness. 16. The stent of claim 14, wherein the inner layer has a variable thickness. 17. The stent of claim 1, wherein the metallic rings have an undulating pattern. 18. The stent of claim 17, wherein the undulating pattern includes U-shaped elements. 19. The stent of claim 1, wherein the stent is configured so that it is visible under any of x-ray fluoroscopy, computer tomography, or MRI. 20. The stent of claim 1, wherein a cavity is formed between the first polymeric material and the second polymeric material so that a therapeutic drug can be releasably contained within the cavity. 21. The stent of claim 1, wherein the metallic rings are formed of struts, the struts having a substantially uniform radial thickness. 22. The stent of claim 1, wherein the metallic rings are formed of struts, the struts having a variable radial thickness. 23. The stent of claim 1, wherein the first polymeric material is a shape memory polymer. 24. The stent of claim 23, wherein the shape memory polymer includes the family of polymers oligo (e-caprolactone) dimethacrylate combined with n-butyl acrylate. 25. A stent, comprising: a plurality of metallic rings aligned along a stent longitudinal axis, each ring having an inner surface and an outer surface; a polymeric layer covering either or both of the inner and outer surfaces of each of the metallic rings, the polymeric layer extending in an area between adjacent metallic rings; and at least two discrete links connecting adjacent metallic rings together, each of the discrete links being formed by the polymeric material in the area between adjacent metallic rings. 26. The stent of claim 25, wherein the polymeric layer is made from EVOH. 27. The stent of claim 25, wherein the polymeric layer is made from PEEK. 28. The stent of claim 25, wherein the discrete links connecting adjacent rings are spaced apart from each other along the circumference of the rings. 29. The stent of claim 25, wherein the discrete links are integral with the polymeric layer covering either or both of the inner and outer surfaces of each of the metallic rings. 30. The stent of claim 25, wherein the polymeric layer is loaded with a therapeutic drug. 31. The stent of claim 25, wherein a cavity is formed on the polymeric layer so that a therapeutic drug can be releasably contained within the cavity. 32. The stent of claim 25, wherein each of the rings is made with a strut having a particular width and the links take the form of a strut having the same or substantially the same width as the struts forming the rings. 33. The stent of claim 25, wherein some of the discrete links have an undulating pattern. 34. A stent, comprising: a plurality of metallic rings aligned along a stent longitudinal axis, each ring having an inner surface and an outer surface; an inner layer of polymeric material extending over the inner surface of each of the metallic rings; an outer layer of polymeric material extending over the outer surface of each of the metallic rings, the inner layer being bonded directly to the outer layer in areas where there is no metallic rings; and at least two discrete links connecting adjacent metallic rings together, each of the discrete links being formed in the area where the inner layer is directly bonded to the outer layer of polymeric material. 35. The stent of claim 34, wherein some of the discrete links have an undulating pattern. 36. The stent of claim 34, wherein each of the discrete links are integral with the inner and outer layers of polymeric material. 37. The stent of claim 34, wherein each of the rings is made with a strut having a particular width and the discrete links take the form of a strut having the same or substantially the same width as the struts forming the rings. 38. The stent of claim 34, wherein the inner and outer layers of polymeric material forming the discrete links are bonded together. 39. The stent of claim 34, wherein one or both of the inner and outer are loaded with a therapeutic drug. 40. The stent of claim 34, wherein a cavity is formed between the inner layer and outer layer so that a therapeutic drug can be releasably contained within the cavity. 41. The stent of claim 40, wherein the cavity is located on at least one of the discrete links. 42. The stent of claim 34, wherein each discrete link connecting adjacent rings is spaced apart from each other along the circumference of the rings. 43. The stent of claim 42, wherein the discrete links are integral with the layers of polymeric material covering the inner and outer surfaces of each of the metallic rings.

Details for Patent 7,959,999

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2022-04-01